Sisli Hamidiye Etfal Training and Resourche Hospital, University of Health Sciences, 34371 Sisli, Istanbul, Turkey.
Sisli Hamidiye Etfal Training and Resourche Hospital, University of Health Sciences, 34371 Sisli, Istanbul, Turkey.
Heart Lung. 2021 May-Jun;50(3):425-429. doi: 10.1016/j.hrtlng.2021.02.009. Epub 2021 Feb 10.
In Covid-19 pneumonia, high mortality rates reported in intubated patients have raised non-invasive methods of respiratory support.
We aimed to evaluate the impact of HFNC application on intubation requirement, intensive care length of stay, and short-term mortality in patients with COVID-19 pneumonia.
MATERIAL-METHOD: Patients receiving oxygen by reservoir mask or HFNC therapy in our intensive care units due to COVID-19 pneumonia were included in the study. Group H consisted of patients who received HFNC, and Group K consisted of patients who received conventional oxygen therapy (COT). The number of patients intubated, duration of intensive care stay and short-term mortality were recorded.
43 patients were included. The short-term mortality and the number of patients with intubation need was lower in Group H. There was no significant difference between the Groups in the length of intensive care stay.
Administration of HFNC in respiratory failure secondary to COVID-19 pneumonia decreases the need for intubation and mortality.
在新冠肺炎肺炎中,报告的插管患者高死亡率引发了对非侵入性呼吸支持方法的研究。
我们旨在评估 HFNC 应用对 COVID-19 肺炎患者插管需求、重症监护停留时间和短期死亡率的影响。
材料-方法:因 COVID-19 肺炎而在我们的重症监护病房中接受储氧面罩或 HFNC 治疗的患者被纳入研究。HFNC 治疗组(H 组)包括接受 HFNC 治疗的患者,常规氧疗组(K 组)包括接受常规氧疗(COT)的患者。记录患者插管的数量、重症监护停留时间和短期死亡率。
共纳入 43 例患者。H 组的短期死亡率和需要插管的患者数量较低。两组患者在重症监护停留时间上无显著差异。
HFNC 在 COVID-19 肺炎继发呼吸衰竭中的应用可降低插管需求和死亡率。